Janux Therapeutics (NASDAQ:JANX) Trading 6.9% Higher

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report)'s stock price was up 6.9% during mid-day trading on Monday . The company traded as high as $37.95 and last traded at $37.53. Approximately 88,027 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 680,019 shares. The stock had previously closed at $35.12.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on JANX shares. Cantor Fitzgerald started coverage on shares of Janux Therapeutics in a report on Wednesday, March 20th. They issued an "overweight" rating and a $100.00 price objective for the company. BTIG Research started coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They set a "buy" rating and a $62.00 price target for the company. Wedbush restated an "outperform" rating and set a $53.00 price target on shares of Janux Therapeutics in a report on Monday, March 11th. Bank of America upped their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, March 13th. Finally, William Blair restated an "outperform" rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Janux Therapeutics presently has an average rating of "Buy" and a consensus price target of $59.60.

Janux Therapeutics Stock Up 10.0 %

The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -28.83 and a beta of 4.18. The company's 50-day moving average is $28.08 and its 200-day moving average is $15.77.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The firm had revenue of $2.46 million during the quarter, compared to analyst estimates of $0.98 million. On average, research analysts forecast that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current year.

Institutional Trading of Janux Therapeutics

Several hedge funds have recently modified their holdings of JANX. Nisa Investment Advisors LLC grew its stake in shares of Janux Therapeutics by 10,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company's stock valued at $29,000 after purchasing an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Janux Therapeutics by 149.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company's stock worth $40,000 after acquiring an additional 2,003 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Janux Therapeutics during the 4th quarter valued at $57,000. Barclays PLC lifted its stake in shares of Janux Therapeutics by 533.0% in the 4th quarter. Barclays PLC now owns 4,608 shares of the company's stock valued at $61,000 after purchasing an additional 3,880 shares during the period. Finally, Citigroup Inc. boosted its position in shares of Janux Therapeutics by 935.2% in the 2nd quarter. Citigroup Inc. now owns 5,787 shares of the company's stock worth $69,000 after purchasing an additional 5,228 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.